文献
J-GLOBAL ID:202102226632653537
整理番号:21A0293683
香港の未治療未分化リンパ腫キナーゼ(ALK)陽性非小細胞肺癌(NSCLC)におけるセリチニブ対クリゾチニブの費用対効果分析【JST・京大機械翻訳】
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
著者 (8件):
Loong Herbert H.
(Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China)
,
Wong Carlos K. H.
(Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, China)
,
Leung Linda K. S.
(Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China)
,
Chan Catherine P. K.
(Novartis Pharmaceuticals Corporation, Hong Kong, China)
,
Chang Andrea
(Novartis Pharmaceuticals Corporation, Hong Kong, China)
,
Zhou Zheng-Yi
(Analysis Group, Inc, London, UK)
,
Xie Jipan
(Analysis Group, Inc, Los Angeles, USA)
,
Gibbs Meaghan
(Novartis Pharmaceuticals Corporation, Dubai, United Arab Emirates)
資料名:
Cost Effectiveness and Resource Allocation (Web)
(Cost Effectiveness and Resource Allocation (Web))
巻:
18
号:
1
ページ:
1-9
発行年:
2020年
JST資料番号:
U7473A
ISSN:
1478-7547
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
イギリス (GBR)
言語:
英語 (EN)